 Equillium, Inc. EQ, a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop products to treat severe autoimmune and inflammatory disorders, today announced that data supporting the role of the CD6-ALCAM pathway as a relevant target for patients with acute graft-versus-host disease aGVHD along with details of the EQUATE Phase 1b2 trial design will be presented at the 61st American Society of Hematology ASH Annual Meeting and Exposition being held from December 7-10, 2019 in Orlando, Florida. Data demonstrating itolizumab efficiently inhibits T cell responses in samples taken from patients with aGVHD received the ASH Abstract Achievement Award. Additionally, data supporting itolizumab as a potential systemic treatment that can modulate pathogenic T effector cell activity in an in vivo model of disease has been published online-only in Blood, the journal of ASH. 